Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?
This article was originally published in The Pink Sheet Daily
Executive Summary
CardioRenal Advisory Committee will discuss whether there should be a trial testing lower dosing limits in CKD patients. With sales declines a forgone conclusion regardless, Amgen hopes to avoid the expense of a complex study.
You may also be interested in...
Aranesp Gets Advisory Committee Boost As Amgen Braces For Labeling Negotiations
FDA panel votes against reducing of darbepoietin alfa in patients with failing kidneys who are headed toward dialysis.
Aranesp Gets Advisory Committee Boost As Amgen Braces For Labeling Negotiations
FDA panel votes against reducing of darbepoietin alfa in patients with failing kidneys who are headed toward dialysis.
FDA Advisory Committee Will Review ESAs In The Renal Setting Oct. 18
Meeting also could be next step in the process of determining whether safety issues are enough to drive changes to erythropoiesis-stimulating agent reimbursement at CMS.